SG11201809672YA - Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives - Google Patents

Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives

Info

Publication number
SG11201809672YA
SG11201809672YA SG11201809672YA SG11201809672YA SG11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA
Authority
SG
Singapore
Prior art keywords
hydroxyalkyl
preparing
triazole derivatives
phenyl
substituted
Prior art date
Application number
SG11201809672YA
Other languages
English (en)
Inventor
Heiko Schirmer
Philipp Rubenbauer
Hans-Christian Militzer
Marie-Pierre Collin-Kröpelin
Frank Süssmeier
Kersten Gericke
Thomas Neubauer
Chantal Fürstner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201809672YA publication Critical patent/SG11201809672YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201809672YA 2016-05-03 2017-05-02 Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives SG11201809672YA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16168169 2016-05-03
EP16168172 2016-05-03
EP16168165 2016-05-03
EP16168166 2016-05-03
EP16168163 2016-05-03
EP17160086 2017-03-09
PCT/EP2017/060367 WO2017191104A1 (de) 2016-05-03 2017-05-02 Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen

Publications (1)

Publication Number Publication Date
SG11201809672YA true SG11201809672YA (en) 2018-11-29

Family

ID=58633014

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809672YA SG11201809672YA (en) 2016-05-03 2017-05-02 Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives

Country Status (18)

Country Link
US (2) US10703742B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452467A1 (cg-RX-API-DMAC7.html)
JP (2) JP6921863B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190003536A (cg-RX-API-DMAC7.html)
CN (2) CN109071500B (cg-RX-API-DMAC7.html)
AU (2) AU2017259872B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072528A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022789A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003107A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018011948A2 (cg-RX-API-DMAC7.html)
IL (1) IL262534B (cg-RX-API-DMAC7.html)
MX (2) MX391356B (cg-RX-API-DMAC7.html)
PE (1) PE20190202A1 (cg-RX-API-DMAC7.html)
RU (1) RU2742885C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201809672YA (cg-RX-API-DMAC7.html)
TW (1) TWI755393B (cg-RX-API-DMAC7.html)
UY (1) UY37222A (cg-RX-API-DMAC7.html)
WO (1) WO2017191104A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191115A1 (en) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
TWI755393B (zh) * 2016-05-03 2022-02-21 德商拜耳製藥股份有限公司 製備5-羥基烷基取代之1-苯基-1,2,4-三唑衍生物之方法
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653332A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
WO2011104322A1 (de) * 2010-02-27 2011-09-01 Bayer Pharma Aktiengesellschaft Bis-arylverknüpfte aryltriazolone und ihre verwendung
ES2641205T3 (es) * 2012-05-08 2017-11-08 Bayer Pharma Aktiengesellschaft Procedimiento para la preparación de compuestos de triazol
CN107074783B (zh) * 2014-11-03 2020-06-05 拜耳制药股份公司 羟烷基取代的苯基三唑衍生物及其用途
WO2017191115A1 (en) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
TWI755393B (zh) * 2016-05-03 2022-02-21 德商拜耳製藥股份有限公司 製備5-羥基烷基取代之1-苯基-1,2,4-三唑衍生物之方法
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof

Also Published As

Publication number Publication date
CN113105403A (zh) 2021-07-13
TW201815782A (zh) 2018-05-01
MX2018013336A (es) 2019-05-09
KR20190003536A (ko) 2019-01-09
WO2017191104A1 (de) 2017-11-09
US10703742B2 (en) 2020-07-07
RU2018142264A (ru) 2020-06-03
JP2021143193A (ja) 2021-09-24
MX391356B (es) 2025-03-19
CN109071500A (zh) 2018-12-21
EP3452467A1 (de) 2019-03-13
AU2017259872B2 (en) 2021-06-24
CA3022789A1 (en) 2017-11-09
UY37222A (es) 2017-11-30
CL2018003107A1 (es) 2019-02-22
JP6921863B2 (ja) 2021-08-18
BR112018072528A2 (pt) 2019-03-26
IL262534B (en) 2021-04-29
MX379555B (es) 2025-03-11
CO2018011948A2 (es) 2018-11-22
CN109071500B (zh) 2021-05-18
RU2742885C2 (ru) 2021-02-11
JP2019514948A (ja) 2019-06-06
AU2021236502A1 (en) 2021-10-21
US20190144431A1 (en) 2019-05-16
TWI755393B (zh) 2022-02-21
AU2017259872A1 (en) 2018-11-22
RU2018142264A3 (cg-RX-API-DMAC7.html) 2020-08-19
MX2020010365A (es) 2022-04-06
IL262534A (en) 2018-12-31
US20200299271A1 (en) 2020-09-24
PE20190202A1 (es) 2019-02-05

Similar Documents

Publication Publication Date Title
SG11201809672YA (en) Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives
IL281196A (en) Process for the preparation of methyl 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo[ 7]Anolene-2-carboxylate
FI119548B (fi) Apolipoproteiini B-synteesin estäjiä
CN102762542B (zh) 一种抗真菌三唑衍生物
MY161482A (en) Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
WO2013042138A3 (en) Process for preparation of triazole antifungal drug, its intermediates and polymorphs thereof
RU2501791C2 (ru) Производное триазола или его соль
CA2727528A1 (en) Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system
JP2017528504A5 (cg-RX-API-DMAC7.html)
JP2018519323A5 (cg-RX-API-DMAC7.html)
TNSN07475A1 (fr) Arylpyrazoles substitues destines a etre utilises contre des parasites
MX2009013626A (es) DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE.
US20230025510A1 (en) Biaryl ether-type quinazoline derivatives
NZ601316A (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
PH12015502088A1 (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
JP2018511613A5 (cg-RX-API-DMAC7.html)
NZ701661A (en) Method for the preparation of triazole compounds
MY198496A (en) Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives
WO2007013096A8 (en) Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole)
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
IL291569A (en) Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-4,2,1-triazol-3-amine
EA202091025A1 (ru) Пролекарства замещенных триазольных производных и их применения
WO2017070718A4 (en) Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of cyp17a1 and cyp19a1
AR076372A1 (es) Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5
IL314283A (en) Methods for preparing ethyl 3-bromo-1-(3-chloropyridin-2-yl)-5,4-dihydro-H1-pyrazole-5-carboxylate